Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus VinorelbineIMAI, Hisao; SHUKUYA, Takehito; MURAKAMI, Haruyasu et al.Chemotherapy (Basel). 2013, Vol 59, Num 4, pp 307-313, issn 0009-3157, 7 p.Article

Clinicopathologic significance of the mutations of the Epidermal Growth Factor Receptor gene in patients with non-small cell lung cancerTOMIZAWA, Yoshio; IIJIMA, Hironobu; DOBASHI, Kunio et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 6816-6822, issn 1078-0432, 7 p., 1Article

Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinomaTOMIZAWA, Yoshio; KOHNO, Takashi; MINNA, John D et al.Clinical cancer research. 2002, Vol 8, Num 7, pp 2362-2368, issn 1078-0432Article

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancerSUNAGA, Noriaki; ORIUCHI, Noboru; KAIRA, Kyoichi et al.Lung cancer. 2008, Vol 59, Num 2, pp 203-210, issn 0169-5002, 8 p.Article

Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancersIIJIMA, Hironobu; TOMIZAWA, Yoshio; IWASAKI, Yasuki et al.International journal of cancer. 2006, Vol 118, Num 4, pp 797-801, issn 0020-7136, 5 p.Article

Clinicopathological significance of aberrant methylation of RARβ2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancerTOMIZAWA, Yoshio; IIJIMA, Hironobu; NOMOTO, Taisuke et al.Lung cancer. 2004, Vol 46, Num 3, pp 305-312, issn 0169-5002, 8 p.Article

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)KAWAGUCHI, Tomoya; ANDO, Masahiko; KAMIMURA, Mitsuhiro et al.Journal of clinical oncology. 2014, Vol 32, Num 18, pp 1902-1908, issn 0732-183X, 7 p.Article

Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapyTOMIZAWA, Yoshio; FUJITA, Yuka; TAMURA, Atsuhisa et al.Lung cancer. 2010, Vol 68, Num 2, pp 269-272, issn 0169-5002, 4 p.Article

Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancersKAIRA, Kyoichi; SUNAGA, Noriaki; TOMIZAWA, Yoshio et al.International journal of oncology. 2007, Vol 31, Num 1, pp 169-173, issn 1019-6439, 5 p.Article

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancerKAIRA, Kyoichi; SUNAGA, Noriaki; YOSHII, Akihiro et al.Lung cancer. 2010, Vol 69, Num 1, pp 99-104, issn 0169-5002, 6 p.Article

Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancerKAIRA, Kyoichi; SUNAGA, Noriaki; HISADA, Takeshi et al.Lung cancer. 2010, Vol 68, Num 2, pp 253-257, issn 0169-5002, 5 p.Article

Phase ii prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapySUNAGA, Noriaki; TOMIZAWA, Yoshio; SAITO, Ryusei et al.Lung cancer. 2007, Vol 56, Num 3, pp 383-389, issn 0169-5002, 7 p.Article

Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cellsKONDO, Masashi; LIN JI; LERMAN, Michael et al.Oncogene (Basingstoke). 2001, Vol 20, Num 43, pp 6258-6262, issn 0950-9232Article

Epigenetic inactivation of the RUNX3 gene in lung cancerSATO, Koji; TOMIZAWA, Yoshio; IUIMA, Hironobu et al.Oncology reports. 2006, Vol 15, Num 1, pp 129-135, issn 1021-335X, 7 p.Article

Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumorsHORIGUCHI, Keishi; TOMIZAWA, Yoshio; TOSAKA, Masahiko et al.Oncogene (Basingstoke). 2003, Vol 22, Num 49, pp 7862-7865, issn 0950-9232, 4 p.Article

Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancerKAIRA, Kyoichi; TOMIZAWA, Yoshio; SATO, Koji et al.Lung cancer. 2013, Vol 82, Num 1, pp 103-108, issn 0169-5002, 6 p.Article

Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancerKAIRA, Kyoichi; TOMIZAWA, Yoshio; HISADA, Takeshi et al.Lung cancer. 2013, Vol 82, Num 3, pp 449-454, issn 0169-5002, 6 p.Article

A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancerKAWAGUCHI, Tomoya; TAKADA, Minoru; SAITO, Ryusei et al.European journal of cancer (1990). 2012, Vol 48, Num 5, pp 672-677, issn 0959-8049, 6 p.Article

Metastasis of hepatocellular carcinoma to the supramaxillary gingiva and right ventricleARAI, Riki; OTSUKA, Toshiyuki; NAKAJIMA, Takashi et al.Hepato-gastroenterology. 2004, Vol 51, Num 58, pp 1159-1161, issn 0172-6390, 3 p.Article

Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancersXU, Xie L; WU, Leeju C; BOWCOCK, Anne M et al.Cancer research (Baltimore). 2001, Vol 61, Num 21, pp 7943-7949, issn 0008-5472Article